Objectives: Atherosclerotic innominate artery stenosis is very rare. Morbidity associated with this condition includes cerebral vascular accidents from hypoperfusion that are very difficult to treat. Traditionally, this condition is treated with either innominate artery stenting or carotid-carotid bypass under general anesthesia. However, we encountered a patient, who could not undergo either treatment due to difficult anatomy for endovascular stenting and prohibitive coronary artery disease for general anesthesia. She was successfully treated with carotid-carotid artery bypass using locoregional anesthesia. Review of the literature identified one case of carotid-carotid bypass without general anesthesia for a patient with acute type B aortic dissection. No prior case of carotid-carotid bypass for innominate artery stenosis under locoregional anesthesia could be identified in the literature.
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Methods: A 68-year-old hypertensive woman presented with a history of cerebrovascular events associated with blood pressure reduction. Cerebral angiography revealed heavily calcified innominate occlusion and right hemispheric flow dependent on the left vertebral artery through diminutive posterior communicating branches. Preoperative cardiac work-up showed significant triple-vessel coronary artery disease making sternotomy and innominate bypass a prohibitive risk. Coronary revascularization to support this was felt to carry an unacceptable cerebrovascular event risk. Endovascular stenting of the calcified innominate artery lesion was felt to carry a high risk for embolic event. In the meanwhile, the patient continued to present with additional episodes of leftsided weakness and numbness despite antiplatelet therapy with aspirin and Plavix. The patient was eventually treated successfully with retroesophageal carotid-carotid bypass with 8-mm polytetrafluoroethylene graft under regional neck nerve block and local anesthesia. The patient expressed only mild discomfort when the retroesophageal tunnel was created. Her airway was intact, and oxygenation remained at 100% throughout the process.
Results: The patient tolerated the procedure well, and she was discharged on postoperative day 1. Follow-up duplex ultrasound imaging of the neck showed patent bypass graft after 1 week. The patient remained free from neurologic symptoms 3 months following the surgery.
Conclusions: Carotid-carotid bypass can be done safely under locoregional anesthesia. Objectives: Carotid angioplasty and stenting (CAS) is an excellent, often superior, alternative to carotid endarterectomy (CEA). When performed by experienced operators, both are equivalent in periprocedural risk and stroke prevention. Widespread adoption of CAS in the United States has been impeded by reimbursement regulations mandated by the Centers for Medicare and Medicaid Services (CMS) that favor CEA over CAS for patients with asymptomatic carotid disease. This policy has led to decreased CAS volumes and an increase in percentages of patients receiving CAS for symptomatic vs asymptomatic disease. Lower CAS volumes lead to institutional challenges in maintaining clinical competency.
Methods: We reviewed records of patients receiving CAS at the University of Texas Medical Branch between July of 2009 and October of 2016. During this time we participated in trials assessing CAS efficacy, allowing patients to receive CMS coverage. We analyzed indications for treatment, preoperative comorbidities, procedural complications, and primary and assisted-primary patency rates. Yearly volumes and outcomes were evaluated to assess for variations associated with changing practice patterns.
Results: There were 215 procedures performed on 195 patients. Mean age was 70 6 10 years. Of the 215 procedures, 153 (78.4%) were performed for symptomatic lesions. There were 111 men (57%) and 84 women (43%) treated. Comorbidities were significant: 94% had hypertension, 87% had hyperlipidemia, 77% were previous or current smokers, 45% had known peripheral arterial disease, 40% had diabetes mellitus, and 31% had previous cardiac interventions. Primary patency was 89.6% with a median follow-up of 26 months. Restenosis occurred in 14 patients (7.1%), with a primary-assisted patency of 99%. Periprocedural neurologic events occurred at a rate of 1.86% (n ¼ 4). No patients in the study group had a myocardial infarction. Yearly variations in volumes were associated with participation in clinical trials that allowed for CMS coverage.
Conclusions: University of Texas Medical Branch's program in CAS has been successful in achieving results superior to most multicenter CAS trials, even in the face of selection bias towards sicker patients with more complicated, symptomatic lesions. While these findings confirm our use of CAS to prevent strokes with low complication rates, regulatory and reimbursement issues are a primary driver of institutional CAS practices. Current reimbursement policies negatively impact on the ability to maintain volumes sufficient to support CAS programs of excellence. Our results endorse expanded CMS coverage for CAS to allow patients the freedom to choose their preferred treatment for any carotid disease requiring intervention.
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